Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell The…

Stanford Medicine

M. Hamilton

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

Rush University Medical Center

C. Brunstein

Pre-Transplant Management of High-Risk AML

Vanderbilt University Medical Center (VUMC)

K. Fedorov

Considering Venetoclax in AML and ALL - Which Patients and Why

Marina Konopleva